Puretek Corpora Patent-Cliff Exposure & CMS Drug Spending Portfolio

Puretek Corpora (US): 38 reconciled FDA prescription therapies, $83.5M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies38
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$83.5M
2024 Medicare Part D Spend$7.0M
2024 Medicaid Spend$76.5M
California HCAI SB 17 Filings6 WAC filings (max 136.3% 2-yr change)